Elemental impurity controls confirmed to ICH Q3D

ICH Q3D, the Guideline for Elemental Impurities, replaced the older reliance on a single non-specific heavy-metals colour test with a science-based framework. It establishes permitted daily exposures (PDEs) for 24 elemental impurities, grouped by toxicity and likelihood of occurrence, and requires manufacturers to assess those impurities against the route of administration and the maximum daily dose of each product. The emphasis falls on a documented risk assessment rather than routine testing alone, with parenteral limits set more conservatively than oral limits for several elements.

“Elemental impurity limits are controlled through a documented risk assessment and validated trace-metal methods, applied to each product by route of administration and maximum daily dose.”

For Ergopharm, the review examined the potential sources of elemental impurities across each product: the drug substance and excipients, the water used in formulation, manufacturing equipment and product-contact surfaces, and the container-closure system. Intentionally added catalysts and reagents were treated as known contributors requiring specific control, while the wider set of elements was evaluated for the likelihood of ingress from materials and processing. The sterile injectable portfolio was assessed against the tighter parenteral PDEs, and the oral solids against the corresponding oral limits.

Where the risk assessment indicated that an element could approach a control threshold, Ergopharm established quantitative acceptance criteria and confirmed analytical procedures capable of measuring at the required trace levels. Validated instrumental methods appropriate to trace-metal analysis are used, with validation carried out in line with the ICH analytical-procedure expectations in force. Results are recorded in the Batch Manufacturing Record and reflected in the Certificate of Analysis, and the control strategy is maintained under change control so that any change to a supplier, material or process route triggers reassessment.

The confirmation applies to Ergopharm's own finished-product controls and processes at the Ergopharm Advanced Research Centre in Vadodara. It is a statement of internal alignment to a harmonised quality guideline and does not represent, and should not be read as, any national marketing approval. All limits referenced are those defined by ICH Q3D and are applied by Ergopharm as part of its pharmaceutical quality system.